
Happy Thursday.
Apparently like half the world is calling in “sick” today to play GTA VI - if you’re one of those, enjoy the day off get well soon.
For my part, in between sick kids and Jensen Huang drama and the daily chaos of managing processes for nearly a dozen investor groups, this week I finally started playing the new Ocarina of Time remake, and let me tell you, it has been one of the most rewarding and nostalgic experiences I’ve had in a long time. Looking forward to some time over the holidays to revisit my childhood.
On to today’s issue:
Angel Deals of the Week | 279 Deals, 131 Networks
First time featured this week: Carolina Angel Network
Bookmarks I think you’ll enjoy
The best nugget from my conversation on Deep Tech Investing 101 with John Forbes of Julian Capital and Deep Checks.
🔥 Angel Deals of the Week
Angel funding rounds announced in recent weeks, compiled from public sources or via direct announcement. These deals represent the elite few that survived an angel network’s vetting process. Note: I have not personally analyzed these companies and am sharing for informational purposes only.
📊 Angel Network Investment Tracker: 279 Deals, 131 Networks.
🔓 The Exclusive: 21 Actively Raising Deals Shared to Date
RootCause.ai | Causal AI business simulation platform
Participating Group: Cowtown Angels
RootCause.ai is developing software that simulates a business (digital twin) so executives can test decisions first, and says one telecom deployment cut forecast error from 20% to 5%. Cowtown Angels recently announced an investment in the company.
Ayman Elhalwagy | San Francisco, CA | November 2026 | Source
Illumion | Battery imaging for materials research
Participating Group: Cambridge Angels
Illumion, a University of Cambridge spinout, is developing imaging technology that lets researchers watch individual battery particles charge and discharge in real time. Cambridge Angels recently announced an investment in the company as part of its $2.3M (£1.7M) round.
Christoph Schnedermann | $2.3M Round | Cambridge, UK | October 2026 | Source
Network Bio | AI models from patient tissue
Participating Group: Carolina Angel Network
Network Bio is developing AI models to detect disease using patient tissue from academic medical centers, which it says include Mass General Brigham. Carolina Angel Network recently announced an investment in the company as part of its $50M financing.
Asad Ali Ahmad | $50M Financing | Palo Alto, CA | October 2026 | Source
Roboze | Industrial 3D printing for aerospace
Participating Group: Club degli Investitori
Roboze makes 3D printers, materials and software for producing aerospace, defense and energy parts on-site, and lists Airbus and NASA as customers. Club degli Investitori recently announced an investment in the company as part of its $10M round.
Alessio Lorusso | $10M Round | Bari, Italy | October 2026 | Source 1, Source 2
Sensible Biotechnologies | Cell-based mRNA design and manufacturing
Participating Group: Springboard Health Angels
Sensible Biotechnologies is developing a way to produce therapeutic mRNA (genetic instructions for making proteins) inside engineered cells, and lists Sartorius as a partner. Springboard Health Angels recently announced an investment in the company’s $15M Series A round.
Miroslav Gasparek | $15M Series A | Oxford, UK | October 2026 | Source
📣 Have an Angel Deal to Announce?

You just read who raised. The Exclusive tells you who's still raising.
When an angel group backs a company, I contact the founder to ask if the round is open. If it is, members get the deck, my memo, and an intro to the founder.
They also get deals that come to me directly and never appear in this newsletter.
$50/month for the first 25 members. 10 seats left. Full refund within 30 days if you’re not enjoying it. Accredited investors only. I’ve shared 21 deals so far.
🔖 Bookmarks
💰 Who Wins in Anthropic’s IPO: WSJ breaks down the 300+ investors lined up for windfalls as Anthropic targets a $1.3+ trillion IPO.
💔 End of an Era at Nvidia: Full timeline of how Jensen Huang went from a report alleging he was a Chinese spy to resigning as CEO in two weeks.
🕹️ Why Everyone Is OOO Today: Per BambooHR, one in five salaried workers plan to call out for GTA VI.
🥇 The Nugget: My Top Takeaway from A Conversation with John Forbes
Bet on the inventor 🔬
One of the first questions I have learned to ask when a technical sounding deal hits my desk is: “Who is running the business here?” Sometimes it’s the inventor. Sometimes it’s not. And both can work, but all else being equal, John shared that he’d take the inventor-founder. Why?
Drive.
Sure, a founder who is simply scaling someone else’s invention might have the right background and a real opportunity in front of them. But John has learned to look for mission-drivenness, and that’s harder to find when someone stumbles onto an idea instead of building it from the ground up.
From John: "Sometimes you'll meet a scientist founder who will tell you straight up, I don't ‘want’ to be a CEO, but the technology that I've built is so compelling and I'm so convinced by the impact that this is going to have on the world that I would lose my mind if this just stayed as a research paper that five people wound up reading."
Takeaway:
Lean in on the reluctant scientist-CEO. Ask why they’re going to all the trouble of building and scaling a business. If the answer sounds less like a “best career move for me” and more like an ‘I’ll die if this stays locked up in the lab’ compulsion, that’s a good sign.
Want more? Check out my full conversation with John 👇
Listen now on Apple Podcasts, Spotify, YouTube, and more.
In Partnership with MarketBeat
7 Companies Leading the Robotics Race
Pretty soon everyone will know these 7 companies leading the robotics race. Find out who they are in MarketBeat’s free report, 7 Stocks to Buy Before the Robotics Revolution.
Until Next Week 👋
Thanks for reading - have a great week.
-Andrew
If you’re finding this newsletter valuable, share it with a friend, and consider subscribing if you haven’t already. You can also find me on LinkedIn and X.
Advertise with The Diligent Observer.







